Hemostemix Inc.
HEM
Rank in Stocks
#32592
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Share Price
$0.04268108
Last synced: 2026-10-21
Market Cap
$9.02M
Change (1 day)
5.73%
Change (1 year)
-42.09%
Country
CA
Trade Hemostemix Inc. (HEM)
Category
Healthcare
Stock price history for Hemostemix Inc. (HEM)
Highest end of day price: $0.04 on 2026-10-01
Lowest end of day price: $0.00 on 2005-11-01
Lowest end of day price: $0.00 on 2005-11-01
Stock price history of Hemostemix Inc. from 2005 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.77 | -3.82% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
